313 related articles for article (PubMed ID: 26375613)
1. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy.
Bröms G; Granath F; Ekbom A; Hellgren K; Pedersen L; Sørensen HT; Stephansson O; Kieler H
Clin Gastroenterol Hepatol; 2016 Feb; 14(2):234-41.e1-5. PubMed ID: 26375613
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden.
Bröms G; Kieler H; Ekbom A; Gissler M; Hellgren K; Lahesmaa-Korpinen AM; Pedersen L; Schmitt-Egenolf M; Sørensen HT; Granath F
Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):316-327. PubMed ID: 32020767
[TBL] [Abstract][Full Text] [Related]
3. Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
Bröms G; Kieler H; Ekbom A; Gissler M; Hellgren K; Leinonen MK; Pedersen L; Schmitt-Egenolf M; Sørensen HT; Granath F
Aliment Pharmacol Ther; 2020 Sep; 52(5):843-854. PubMed ID: 32706178
[TBL] [Abstract][Full Text] [Related]
4. Newer-generation antiepileptic drugs and the risk of major birth defects.
Mølgaard-Nielsen D; Hviid A
JAMA; 2011 May; 305(19):1996-2002. PubMed ID: 21586715
[TBL] [Abstract][Full Text] [Related]
5. Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
Bröms G; Granath F; Stephansson O; Kieler H
Scand J Gastroenterol; 2016 Dec; 51(12):1462-1469. PubMed ID: 27739352
[TBL] [Abstract][Full Text] [Related]
6. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
7. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate-severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight.
Kammerlander H; Nielsen J; Knudsen T; Kjeldsen J; Friedman S; Nørgård BM
Inflamm Bowel Dis; 2017 Nov; 23(11):1916-1923. PubMed ID: 28858070
[TBL] [Abstract][Full Text] [Related]
9. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis.
Komaki F; Komaki Y; Micic D; Ido A; Sakuraba A
J Autoimmun; 2017 Jan; 76():38-52. PubMed ID: 27913060
[TBL] [Abstract][Full Text] [Related]
10. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation.
Skomsvoll JF; Wallenius M; Koksvik HS; Rødevand E; Salvesen KA; Spigset O; Kvien TK
Nat Clin Pract Rheumatol; 2007 Mar; 3(3):156-64. PubMed ID: 17334338
[TBL] [Abstract][Full Text] [Related]
11. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study.
Andersen SL; Olsen J; Wu CS; Laurberg P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4373-81. PubMed ID: 24151287
[TBL] [Abstract][Full Text] [Related]
12. Maternal Thyroid Function, Use of Antithyroid Drugs in Early Pregnancy, and Birth Defects.
Andersen SL; Knøsgaard L; Olsen J; Vestergaard P; Andersen S
J Clin Endocrinol Metab; 2019 Dec; 104(12):6040-6048. PubMed ID: 31408173
[TBL] [Abstract][Full Text] [Related]
13. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects.
Pasternak B; Hviid A
JAMA; 2010 Aug; 304(8):859-66. PubMed ID: 20736469
[TBL] [Abstract][Full Text] [Related]
14. Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-α Agents Before Conception.
Larsen MD; Friedman S; Magnussen B; Nørgård BM
Am J Gastroenterol; 2016 Nov; 111(11):1608-1613. PubMed ID: 27619836
[TBL] [Abstract][Full Text] [Related]
15. Maternal obesity and morbid obesity: the risk for birth defects in the offspring.
Blomberg MI; Källén B
Birth Defects Res A Clin Mol Teratol; 2010 Jan; 88(1):35-40. PubMed ID: 19711433
[TBL] [Abstract][Full Text] [Related]
16. Neonatal and maternal outcome after blastocyst transfer: a population-based registry study.
Ginström Ernstad E; Bergh C; Khatibi A; Källén KB; Westlander G; Nilsson S; Wennerholm UB
Am J Obstet Gynecol; 2016 Mar; 214(3):378.e1-378.e10. PubMed ID: 26928152
[TBL] [Abstract][Full Text] [Related]
17. Severity of birth defects after propylthiouracil exposure in early pregnancy.
Andersen SL; Olsen J; Wu CS; Laurberg P
Thyroid; 2014 Oct; 24(10):1533-40. PubMed ID: 24963758
[TBL] [Abstract][Full Text] [Related]
18. Increased congenital heart defects in children born to women with systemic lupus erythematosus: results from the offspring of Systemic Lupus Erythematosus Mothers Registry Study.
Vinet É; Pineau CA; Scott S; Clarke AE; Platt RW; Bernatsky S
Circulation; 2015 Jan; 131(2):149-56. PubMed ID: 25355915
[TBL] [Abstract][Full Text] [Related]
19. The health consequences of teenage fertility.
Makinson C
Fam Plann Perspect; 1985; 17(3):132-9. PubMed ID: 2431924
[TBL] [Abstract][Full Text] [Related]
20. Risk of adverse birth outcomes after maternal varenicline use: A population-based observational study in Denmark and Sweden.
Pedersen L; Petronis KR; Nørgaard M; Mo J; Frøslev T; Stephansson O; Granath F; Kieler H; Sørensen HT
Pharmacoepidemiol Drug Saf; 2020 Jan; 29(1):94-102. PubMed ID: 31713302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
